Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer
- 1 February 2002
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (1) , 78-86
- https://doi.org/10.1053/sonc.2002.31528
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung CancerChest, 2000
- The Hallmarks of CancerCell, 2000
- Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non–Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Preclinical and Clinical Studies of MMP Inhibitors in CancerAnnals of the New York Academy of Sciences, 1999
- Matrix metalloproteinases and metastasisCancer Chemotherapy and Pharmacology, 1999
- Matrix metalloproteinases in angiogenesis: a moving target for therapeutic interventionJournal of Clinical Investigation, 1999
- Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and EtoposideNew England Journal of Medicine, 1999
- ECM and Cell Surface Proteolysis: Regulating Cellular EcologyCell, 1997
- Changing views of the role of matrix metalloproteinases in metastasisJNCI Journal of the National Cancer Institute, 1997
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995